Publications by authors named "Mª Teresa Diz-Lois Palomares"
Article Synopsis
- Ustekinumab is approved for treating ulcerative colitis (UC), and this study evaluated its long-term effectiveness and tolerability in real clinical settings.
- In a multicenter analysis of 620 UC patients, 25% discontinued treatment, with baseline anemia, steroid use, and severe disease linked to higher discontinuation rates.
- At 16 weeks, 40% of patients were in steroid-free remission, and treatment was generally safe with no adverse effects on other conditions, indicating good long-term durability for difficult-to-treat cases.
Article Synopsis
- Measuring trough concentrations of biological drugs and anti-drug antibodies is important for optimizing treatments, with ELISA being the traditional method used.
- A study compared drug levels and antibody concentrations using a new chemiluminescence technique (i-TRACK) to the established ELISA method (TRITURUS) for drugs like infliximab, adalimumab, vedolizumab, and ustekinumab.
- While both methods showed excellent correlation for measuring drug concentrations, the chemiluminescent technique generally reported lower values, and further research is needed for ustekinumab and vedolizumab due to modest results.
Introduction: The objective of this study was to assess the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice.
Methods: This is a retrospective multicenter study including patients with UC who had received the first tofacitinib dose at least 8 weeks before the inclusion. Clinical effectiveness was based on partial Mayo score.
The authors wish to make the following corrections to this paper [...
View Article and Find Full Text PDFUstekinumab has shown efficacy in Crohn's Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning.
View Article and Find Full Text PDFArticle Synopsis
- An observational study tracked patient outcomes, including clinical parameters and adalimumab levels, over a year, showing that most patients maintained their response to treatment.
- The switch led to significant cost savings, reducing treatment expenses from about €16,276 to €8,812 per patient annually, despite some patients experiencing mild symptom fluctuations.
Background: Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn's disease (CD) patients in real-world clinical practice.
Methods: A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety.
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year.
View Article and Find Full Text PDFWe present the case of a 39-year-old male treated with Etanercept and debut of inflammatory bowel disease 11 months later. A literature review of the possible relationship between the debut and the treatment with Etanercept is done.
View Article and Find Full Text PDF